Digma Secures $27 Million in Funding to Revolutionize Diabetes Treatment with Endoscopic Glycemic Management (EGM)

We are thrilled to announce that Digma has successfully raised $27 million in funding to advance our mission of revolutionizing diabetes care through innovative therapies. As a pioneer in the field, Digma focuses on leveraging the power of the small intestine to provide patients and healthcare providers an effective, safe, and minimally invasive treatment option for type 2 diabetes. Our groundbreaking therapy, known as Endoscopic Glycemic Management (EGM), is designed to restore the body’s ability to regulate blood glucose levels naturally. By targeting the duodenal submucosa, which plays a critical role in nutrient sensing and metabolic signaling, we aim to significantly enhance patients' quality of life and long-term health outcomes. The EGM procedure is unique not only in its approach but also in its compatibility with standard gastrointestinal endoscopes, allowing it to be performed in a regular GI endoscopy suite without the need for complex additional imaging equipment. This new funding will be instrumental in advancing our clinical studies and bringing our innovative solution to market. We are committed to ensuring that our patients experience durable improvements in glycemic control with minimal side effects and without the burden of additional daily medical therapies. As we move forward, we invite those interested in learning more about our clinical program and the exciting prospects of Digma to reach out to us. Together, we are paving the way for a healthier future for individuals living with type 2 diabetes.